---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-050844"
form_type: "8-K"
ticker: "IRD"
cik: "0001228627"
company_name: "Opus Genetics, Inc."
filed_at: "2023-11-01T23:59:59+00:00"
generated_at: "2026-06-09T02:03:40.022526+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ocuphire appoints George Magrath as CEO effective Nov 1; awards 1M equity shares

## Summary
- Dr. George Magrath appointed CEO and board member, effective Nov 1, 2023; succeeds interim CEO Rick Rodgers who remains on board.
- Employment agreement: $575,000 base salary, 55% target bonus, 600,000 stock options and 400,000 RSUs as inducement grants.
- Inducement plan increased by 2,000,000 shares to total 2,325,258 shares available for equity awards.
- Magrath previously CEO of Lexitas Pharmaceutical Services; led acquisition and growth in ophthalmic CRO.
- Committee composition changed effective Nov 15: Cam Gallagher chairs audit, James Manuso chairs compensation, Richard Rodgers chairs nominating.

## SEC filing metadata
- accession: 0001140361-23-050844
- form_type: 8-K
- ticker: IRD
- cik: 0001228627
- company_name: Opus Genetics, Inc.
- filed_at: 2023-11-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1228627/000114036123050844/0001140361-23-050844-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1228627/000114036123050844/ef20013742_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-050844
- JSON: https://secwatch.observer/filing/0001140361-23-050844.json
- Plain text: https://secwatch.observer/filing/0001140361-23-050844.txt

## Key facts
- Executive change
  Dr. George Magrath was appointed as Chief Executive Officer at Opus Genetics, Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: On October 30 , 2023, the Board of Directors (the “Board” ) of Ocuphire Pharma, Inc. (the “Company” ) appointed Dr. George Magrath, age 39, as the Company’s Chief Executive Officer, effective as of November 1, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1228627/000114036123050844/0001140361-23-050844-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.